Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acoramidis (Primary)
  • Indications Amyloidosis
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Eidos Therapeutics

    • Most Recent Events

    • 17 Sep 2018 According to an Eidos Therapeutics media release, results from this study were presented during a poster session at the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA).
    • 17 Sep 2018 Results presented in an Eidos Therapeutics media release.
    • 07 Aug 2018 According to an Eidos Therapeutics media release, complete data will be presented at poster presentation at Heart Failure Society of America 22nd Annual Scientific Meeting in September 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top